GSK Advances Ovarian Cancer Drug Mo-Rez Through Clinical Pipeline

GSK is advancing mo-rez, its ovarian cancer drug candidate, through clinical development with positive momentum. The drug is progressing through trials with encouraging signals for patients with ovarian cancer, per STAT News biotech coverage.